Browse the evidence

Liraglutide shows a statistically significant disproportionality signal for completed suicide, but this is likely due to statistical fragility, small case numbers, and notoriety bias rather than a true pharmacological effect.

While Liraglutide shows a statistical signal for completed suicide in reporting databases, this is based on a very small number of cases (14) and is likely influenced by reporting bias. It should not be interpreted as evidence of increased risk.

Tirzepatide mitigates ischemic stroke damage by restoring Blood-Brain Barrier (BBB) integrity via Claudin-1 expression and reducing neuroinflammation.

This finding is currently limited to animal studies. While promising for stroke recovery, it does not yet translate to a standard human treatment protocol for acute stroke.

The report discusses key factors that may influence consumption, health, food production and processing, food marketing and labelling.

Practitioners should be aware of these factors when addressing nutrition and health.

Illicit use of AAS by competitive athletes is contrary to the rules and ethics of many sport governing bodies.

Athletes should be aware of the ethical implications and potential consequences of AAS use.

High-quality studies are needed to provide definitive answers regarding the safety and duration of preoperative drug cessation for GLP-1-RAs.

Clinicians should advocate for more research to establish clear guidelines for GLP-1-RAs in the perioperative context.

The economic stimulus program should invest part of the estimated $700 billion in a national initiative to prevent obesity.

Investing in obesity prevention can lead to public health and economic benefits.

Current obesity-related costs amount to more than $100 billion per year, representing 5% to 7% of annual health care expenditures.

Understanding the economic burden of obesity can help prioritize public health initiatives.

There are numerous research opportunities to explore the use of metabolic and bariatric surgery and obesity pharmacotherapy for cancer prevention.

Researchers should focus on investigating the cancer prevention potential of obesity treatments.

Long-term data on the efficacy and safety of Tirzepatide are still forthcoming.

Practitioners should remain cautious and await further data on long-term outcomes before fully endorsing TZP.

Pharmacovigilance is vital in real-world settings due to the absence of sufficiently long-term studies.

Clinicians should remain vigilant about the long-term effects of AOMs in practice.

The high pricing of semaglutide (₹17,000–26,000/month) threatens equitable access.

Practitioners should be aware of the cost barriers that may limit patient access to semaglutide.

There is a need for a better understanding of reimbursement mechanisms related to obesity prevention and management.

Practitioners should advocate for improved understanding and policies regarding reimbursement for obesity management.

There are challenges inherent in scientific evidence regarding nutrition.

Practitioners should be aware of the complexities and uncertainties in nutritional science.

Beta-amyrin acetate, a compound derived from the medicinal fungus Poria cocos, acts as a putative antagonist of the Neuropeptide Y1 receptor (Y1R) by binding to the orthosteric site with high affinity, potentially inhibiting feeding behavior associated with obesity.

Beta-amyrin acetate is a specific chemical compound found in the fungus Poria cocos. Current research is purely computational (computer simulations), predicting it might block a specific brain receptor (Y1R) involved in hunger. There is no human dosing protocol or clinical evidence yet; do not use this as a weight loss treatment based on this paper alone.

BMI categories are arbitrary classifications that do not accurately reflect health risks or body fat levels, and using them as a proxy for disease leads to misdiagnosis and stigma.

Do not rely on BMI alone to determine your health. It is an arbitrary cutoff that fails to account for muscle mass or individual health markers. Focus on how you feel, your fitness, and metabolic health markers rather than a number on a scale.

Bariatric surgery (RYGB, sleeve gastrectomy) does not result in clinically significant improvements in semen volume, sperm concentration, morphology, or DNA damage in men with obesity.

Do not expect bariatric surgery to improve your fertility. While it helps with weight, studies show it does not significantly improve sperm quality or DNA integrity. If fertility is a priority, lifestyle changes are a more reliable first step.

Non-peptide small molecule agonists targeting the GLP-1 receptor orthosteric site can achieve binding affinities and stability comparable to or exceeding existing peptide-based GLP-1RAs, suggesting a viable mechanism for oral administration.

This paper does not offer a current treatment but identifies potential oral drug candidates. It suggests that future oral GLP-1 medications may exist that are as effective as current injectables, addressing the common desire to avoid injections.

The LPAR1 antagonist EPGN2154, administered orally at 10 mg/kg, significantly reduces hepatic fibrosis and improves liver histology in preclinical NASH models, independent of body weight loss.

This research identifies a specific drug candidate (EPGN2154) that targets liver fibrosis directly through receptor antagonism, rather than just reducing body weight. While not yet available for humans, it highlights that treating NASH may require specific molecular interventions beyond just weight loss, particularly for fibrosis regression.

Combination therapy of the LPAR1 antagonist EPGN2154 and the GLP-1 agonist Semaglutide results in the maximum body weight loss and fat mass reduction in diet-induced obese mice, outperforming either drug alone.

Combining a GLP-1 agonist (like Semaglutide) with an LPAR1 antagonist (like EPGN2154) appears to maximize weight loss in preclinical models, potentially offering a synergistic effect for obesity management.

Self-administered overdose of Semaglutide (up to 8x the weekly dose) can cause multiorgan failure, including acute kidney injury, cholestatic liver dysfunction, and gastrointestinal bleeding, in patients with Type 2 Diabetes.

If you are using Semaglutide, never inject more than the prescribed weekly dose, even if you feel you need to 'catch up' or are experiencing side effects. The delivery pen allows you to inject multiple times, which can lead to life-threatening organ failure. If you feel dysphoric or suicidal, seek immediate help and do not attempt to self-medicate or overdose.

For heart failure treatment, diuretics are more effective than exercise interventions in reducing mortality.

If you have heart failure, standard drug treatments (specifically diuretics and beta-blockers) are currently more effective than exercise alone at reducing mortality risk. Exercise should be considered a complementary therapy, not a replacement for medication.

Laser-assisted uvulopalatoplasty (LAUP) is not routinely recommended for treating obstructive sleep apnea syndrome due to lack of AHI normalization and potential for worsening.

Do not pursue laser uvula surgery (LAUP) for sleep apnea. It is not recommended because it rarely fixes the breathing pauses and can sometimes make them worse. The pain and risks of the procedure outweigh the lack of benefit.

Synthetic agonists of the NR4A subgroup (e.g., 6-mercaptopurine, cytosporone B) can modulate receptor activity to potentially treat metabolic and cardiovascular diseases, although their clinical utility is currently limited by poor potency and lack of endogenous ligand specificity.

Researchers have identified synthetic drugs that can activate NR4A receptors, which might help treat obesity and diabetes in the future. However, these drugs are currently just research tools with weak effects and unknown long-term safety. For now, the best way to activate these beneficial receptors is through natural stimuli like exercise and healthy eating, which the body is evolved to handle.

Current assays for measuring testosterone and free testosterone in women are inadequate due to lack of sensitivity and specificity, necessitating the development of more accurate methods.

Be aware that standard testosterone tests may not be accurate for women because they are designed for higher male levels. If you are concerned about hormone levels, ask your doctor about the limitations of the test used and whether more sensitive methods (like mass spectrometry) are available.